Research Analysts Offer Predictions for SCYNEXIS FY2029 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Investment analysts at Brookline Capital Management issued their FY2029 EPS estimates for shares of SCYNEXIS in a note issued to investors on Thursday, March 13th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn $0.39 per share for the year.

Separately, StockNews.com downgraded SCYNEXIS from a “hold” rating to a “sell” rating in a report on Thursday, March 13th.

SCYNEXIS Price Performance

SCYX opened at $1.10 on Monday. The business has a fifty day simple moving average of $1.08 and a 200 day simple moving average of $1.25. SCYNEXIS has a 1 year low of $0.82 and a 1 year high of $3.07. The company has a market capitalization of $42.88 million, a PE ratio of -1.49 and a beta of 1.67.

SCYNEXIS (NASDAQ:SCYX) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The company had revenue of $0.98 million during the quarter. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%.

Institutional Trading of SCYNEXIS

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in SCYNEXIS in the 3rd quarter valued at $25,000. Geode Capital Management LLC increased its position in shares of SCYNEXIS by 10.0% in the third quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock worth $594,000 after purchasing an additional 36,405 shares during the period. AMH Equity Ltd raised its stake in SCYNEXIS by 4.3% in the fourth quarter. AMH Equity Ltd now owns 626,052 shares of the company’s stock valued at $758,000 after purchasing an additional 26,052 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in SCYNEXIS during the fourth quarter worth about $49,000. Finally, Two Sigma Securities LLC bought a new stake in SCYNEXIS during the fourth quarter worth about $25,000. Institutional investors own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.